Prime Medicine, Inc. (NASDAQ: PRME) Stock Competitors & Peer Comparison
See PRME's competitors and their performance on the NASDAQ and across the wider stock market.
Peer Comparison Table: Biotechnology Industry
Detailed financial metrics including price, market cap, P/E ratio, and more for PRME and its NASDAQ peers.
| Symbol | Price | Change % | Market Cap | P/E Ratio | EPS | Dividend Yield |
|---|---|---|---|---|---|---|
| PRME | $3.00 | +1.53% | 543.7M | -2.45 | -$1.23 | N/A |
| VRTX | $484.67 | +1.53% | 121.6B | 25.45 | $18.82 | N/A |
| VRNA | $106.91 | +0.11% | 72.7B | -102.80 | -$1.04 | N/A |
| REGN | $686.20 | +4.60% | 68.7B | 14.62 | $45.63 | +0.54% |
| ARGX | $876.05 | -4.59% | 55.3B | 80.22 | $11.08 | N/A |
| SGEN | $228.74 | -0.07% | 43.2B | -57.19 | -$4.00 | N/A |
| RVMD | $182.58 | -3.51% | 40B | -26.60 | -$7.07 | N/A |
| RVMDW | $8.80 | -7.37% | 39.8B | -2.27 | -$4.15 | N/A |
| ALNY | $286.21 | +5.31% | 37.2B | 50.16 | $5.55 | N/A |
| ONC | $326.83 | +0.29% | 34.8B | 72.91 | $4.47 | N/A |
Stock Comparison
Vertex Pharmaceuticals Incorporated (NASDAQ: VRTX)
PRME vs VRTX Comparison July 2026
Prime Medicine, Inc. (NASDAQ: PRME) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, PRME stands at 543.7M. In comparison, VRTX has a market cap of 121.6B. Regarding current trading prices, PRME is priced at $3.00 on the NASDAQ, while VRTX trades at $484.67.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
PRME currently has a P/E ratio of -2.45, whereas VRTX's P/E ratio is 25.45. In terms of profitability, PRME's ROE is -1.89%, compared to VRTX's ROE of +0.24%. Regarding short-term risk, PRME is more volatile compared to VRTX. This indicates higher risk in terms of short-term price fluctuations for PRME.Check VRTX's competition here
Verona Pharma plc (NASDAQ: VRNA)
PRME vs VRNA Comparison July 2026
Prime Medicine, Inc. (NASDAQ: PRME) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, PRME stands at 543.7M. In comparison, VRNA has a market cap of 72.7B. Regarding current trading prices, PRME is priced at $3.00 on the NASDAQ, while VRNA trades at $106.91.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
PRME currently has a P/E ratio of -2.45, whereas VRNA's P/E ratio is -102.80. In terms of profitability, PRME's ROE is -1.89%, compared to VRNA's ROE of -0.02%. Regarding short-term risk, PRME is more volatile compared to VRNA. This indicates higher risk in terms of short-term price fluctuations for PRME.Check VRNA's competition here
Regeneron Pharmaceuticals, Inc. (NASDAQ: REGN)
PRME vs REGN Comparison July 2026
Prime Medicine, Inc. (NASDAQ: PRME) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, PRME stands at 543.7M. In comparison, REGN has a market cap of 68.7B. Regarding current trading prices, PRME is priced at $3.00 on the NASDAQ, while REGN trades at $686.20.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
PRME currently has a P/E ratio of -2.45, whereas REGN's P/E ratio is 14.62. In terms of profitability, PRME's ROE is -1.89%, compared to REGN's ROE of +0.14%. Regarding short-term risk, PRME is more volatile compared to REGN. This indicates higher risk in terms of short-term price fluctuations for PRME.Check REGN's competition here
argenx SE (NASDAQ: ARGX)
PRME vs ARGX Comparison July 2026
Prime Medicine, Inc. (NASDAQ: PRME) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, PRME stands at 543.7M. In comparison, ARGX has a market cap of 55.3B. Regarding current trading prices, PRME is priced at $3.00 on the NASDAQ, while ARGX trades at $876.05.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
PRME currently has a P/E ratio of -2.45, whereas ARGX's P/E ratio is 80.22. In terms of profitability, PRME's ROE is -1.89%, compared to ARGX's ROE of +0.32%. Regarding short-term risk, PRME is more volatile compared to ARGX. This indicates higher risk in terms of short-term price fluctuations for PRME.Check ARGX's competition here
Seagen Inc. (NASDAQ: SGEN)
PRME vs SGEN Comparison July 2026
Prime Medicine, Inc. (NASDAQ: PRME) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, PRME stands at 543.7M. In comparison, SGEN has a market cap of 43.2B. Regarding current trading prices, PRME is priced at $3.00 on the NASDAQ, while SGEN trades at $228.74.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
PRME currently has a P/E ratio of -2.45, whereas SGEN's P/E ratio is -57.19. In terms of profitability, PRME's ROE is -1.89%, compared to SGEN's ROE of -0.21%. Regarding short-term risk, PRME is more volatile compared to SGEN. This indicates higher risk in terms of short-term price fluctuations for PRME.Check SGEN's competition here
Revolution Medicines, Inc. (NASDAQ: RVMD)
PRME vs RVMD Comparison July 2026
Prime Medicine, Inc. (NASDAQ: PRME) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, PRME stands at 543.7M. In comparison, RVMD has a market cap of 40B. Regarding current trading prices, PRME is priced at $3.00 on the NASDAQ, while RVMD trades at $182.58.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
PRME currently has a P/E ratio of -2.45, whereas RVMD's P/E ratio is -26.60. In terms of profitability, PRME's ROE is -1.89%, compared to RVMD's ROE of -0.83%. Regarding short-term risk, PRME is more volatile compared to RVMD. This indicates higher risk in terms of short-term price fluctuations for PRME.Check RVMD's competition here
Revolution Medicines, Inc. Warrant (NASDAQ: RVMDW)
PRME vs RVMDW Comparison July 2026
Prime Medicine, Inc. (NASDAQ: PRME) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, PRME stands at 543.7M. In comparison, RVMDW has a market cap of 39.8B. Regarding current trading prices, PRME is priced at $3.00 on the NASDAQ, while RVMDW trades at $8.80.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
PRME currently has a P/E ratio of -2.45, whereas RVMDW's P/E ratio is -2.27. In terms of profitability, PRME's ROE is -1.89%, compared to RVMDW's ROE of -0.83%. Regarding short-term risk, PRME is less volatile compared to RVMDW. This indicates lower risk in terms of short-term price fluctuations for PRME.Check RVMDW's competition here
Alnylam Pharmaceuticals, Inc. (NASDAQ: ALNY)
PRME vs ALNY Comparison July 2026
Prime Medicine, Inc. (NASDAQ: PRME) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, PRME stands at 543.7M. In comparison, ALNY has a market cap of 37.2B. Regarding current trading prices, PRME is priced at $3.00 on the NASDAQ, while ALNY trades at $286.21.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
PRME currently has a P/E ratio of -2.45, whereas ALNY's P/E ratio is 50.16. In terms of profitability, PRME's ROE is -1.89%, compared to ALNY's ROE of +0.98%. Regarding short-term risk, PRME is more volatile compared to ALNY. This indicates higher risk in terms of short-term price fluctuations for PRME.Check ALNY's competition here
BeOne Medicines AG (NASDAQ: ONC)
PRME vs ONC Comparison July 2026
Prime Medicine, Inc. (NASDAQ: PRME) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, PRME stands at 543.7M. In comparison, ONC has a market cap of 34.8B. Regarding current trading prices, PRME is priced at $3.00 on the NASDAQ, while ONC trades at $326.83.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
PRME currently has a P/E ratio of -2.45, whereas ONC's P/E ratio is 72.91. In terms of profitability, PRME's ROE is -1.89%, compared to ONC's ROE of +0.12%. Regarding short-term risk, PRME is more volatile compared to ONC. This indicates higher risk in terms of short-term price fluctuations for PRME.Check ONC's competition here
Roivant Sciences Ltd. (NASDAQ: ROIV)
PRME vs ROIV Comparison July 2026
Prime Medicine, Inc. (NASDAQ: PRME) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, PRME stands at 543.7M. In comparison, ROIV has a market cap of 25B. Regarding current trading prices, PRME is priced at $3.00 on the NASDAQ, while ROIV trades at $33.86.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
PRME currently has a P/E ratio of -2.45, whereas ROIV's P/E ratio is -35.69. In terms of profitability, PRME's ROE is -1.89%, compared to ROIV's ROE of -0.07%. Regarding short-term risk, PRME is more volatile compared to ROIV. This indicates higher risk in terms of short-term price fluctuations for PRME.Check ROIV's competition here
Incyte Corporation (NASDAQ: INCY)
PRME vs INCY Comparison July 2026
Prime Medicine, Inc. (NASDAQ: PRME) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, PRME stands at 543.7M. In comparison, INCY has a market cap of 23.7B. Regarding current trading prices, PRME is priced at $3.00 on the NASDAQ, while INCY trades at $127.38.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
PRME currently has a P/E ratio of -2.45, whereas INCY's P/E ratio is 15.98. In terms of profitability, PRME's ROE is -1.89%, compared to INCY's ROE of +0.29%. Regarding short-term risk, PRME is less volatile compared to INCY. This indicates lower risk in terms of short-term price fluctuations for PRME.Check INCY's competition here
BioNTech SE (NASDAQ: BNTX)
PRME vs BNTX Comparison July 2026
Prime Medicine, Inc. (NASDAQ: PRME) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, PRME stands at 543.7M. In comparison, BNTX has a market cap of 23B. Regarding current trading prices, PRME is priced at $3.00 on the NASDAQ, while BNTX trades at $91.79.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
PRME currently has a P/E ratio of -2.45, whereas BNTX's P/E ratio is -19.72. In terms of profitability, PRME's ROE is -1.89%, compared to BNTX's ROE of -0.07%. Regarding short-term risk, PRME is more volatile compared to BNTX. This indicates higher risk in terms of short-term price fluctuations for PRME.Check BNTX's competition here
Insmed Incorporated (NASDAQ: INSM)
PRME vs INSM Comparison July 2026
Prime Medicine, Inc. (NASDAQ: PRME) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, PRME stands at 543.7M. In comparison, INSM has a market cap of 22.7B. Regarding current trading prices, PRME is priced at $3.00 on the NASDAQ, while INSM trades at $104.52.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
PRME currently has a P/E ratio of -2.45, whereas INSM's P/E ratio is -18.21. In terms of profitability, PRME's ROE is -1.89%, compared to INSM's ROE of -1.30%. Regarding short-term risk, PRME is more volatile compared to INSM. This indicates higher risk in terms of short-term price fluctuations for PRME.Check INSM's competition here
United Therapeutics Corporation (NASDAQ: UTHR)
PRME vs UTHR Comparison July 2026
Prime Medicine, Inc. (NASDAQ: PRME) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, PRME stands at 543.7M. In comparison, UTHR has a market cap of 22.4B. Regarding current trading prices, PRME is priced at $3.00 on the NASDAQ, while UTHR trades at $527.08.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
PRME currently has a P/E ratio of -2.45, whereas UTHR's P/E ratio is 19.49. In terms of profitability, PRME's ROE is -1.89%, compared to UTHR's ROE of +0.19%. Regarding short-term risk, PRME is more volatile compared to UTHR. This indicates higher risk in terms of short-term price fluctuations for PRME.Check UTHR's competition here
Moderna, Inc. (NASDAQ: MRNA)
PRME vs MRNA Comparison July 2026
Prime Medicine, Inc. (NASDAQ: PRME) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, PRME stands at 543.7M. In comparison, MRNA has a market cap of 22.1B. Regarding current trading prices, PRME is priced at $3.00 on the NASDAQ, while MRNA trades at $55.27.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
PRME currently has a P/E ratio of -2.45, whereas MRNA's P/E ratio is -6.83. In terms of profitability, PRME's ROE is -1.89%, compared to MRNA's ROE of -0.37%. Regarding short-term risk, PRME is more volatile compared to MRNA. This indicates higher risk in terms of short-term price fluctuations for PRME.Check MRNA's competition here
BeiGene, Ltd. (NASDAQ: BGNE)
PRME vs BGNE Comparison July 2026
Prime Medicine, Inc. (NASDAQ: PRME) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, PRME stands at 543.7M. In comparison, BGNE has a market cap of 20.2B. Regarding current trading prices, PRME is priced at $3.00 on the NASDAQ, while BGNE trades at $184.71.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
PRME currently has a P/E ratio of -2.45, whereas BGNE's P/E ratio is -22.55. In terms of profitability, PRME's ROE is -1.89%, compared to BGNE's ROE of +0.12%. Regarding short-term risk, PRME is more volatile compared to BGNE. This indicates higher risk in terms of short-term price fluctuations for PRME.Check BGNE's competition here
Ginkgo Bioworks Holdings, Inc. WT (NYSE: DNA-WT)
PRME vs DNA-WT Comparison July 2026
Prime Medicine, Inc. (NASDAQ: PRME) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, PRME stands at 543.7M. In comparison, DNA-WT has a market cap of 18.7B. Regarding current trading prices, PRME is priced at $3.00 on the NASDAQ, while DNA-WT trades at $0.27.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
PRME currently has a P/E ratio of -2.45, whereas DNA-WT's P/E ratio is N/A. In terms of profitability, PRME's ROE is -1.89%, compared to DNA-WT's ROE of -0.57%. Regarding short-term risk, PRME is more volatile compared to DNA-WT. This indicates higher risk in terms of short-term price fluctuations for PRME.Check DNA-WT's competition here
Neurocrine Biosciences, Inc. (NASDAQ: NBIX)
PRME vs NBIX Comparison July 2026
Prime Medicine, Inc. (NASDAQ: PRME) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, PRME stands at 543.7M. In comparison, NBIX has a market cap of 17.7B. Regarding current trading prices, PRME is priced at $3.00 on the NASDAQ, while NBIX trades at $180.69.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
PRME currently has a P/E ratio of -2.45, whereas NBIX's P/E ratio is 25.49. In terms of profitability, PRME's ROE is -1.89%, compared to NBIX's ROE of +0.22%. Regarding short-term risk, PRME is more volatile compared to NBIX. This indicates higher risk in terms of short-term price fluctuations for PRME.Check NBIX's competition here
Genmab A/S (NASDAQ: GMAB)
PRME vs GMAB Comparison July 2026
Prime Medicine, Inc. (NASDAQ: PRME) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, PRME stands at 543.7M. In comparison, GMAB has a market cap of 17.7B. Regarding current trading prices, PRME is priced at $3.00 on the NASDAQ, while GMAB trades at $29.13.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
PRME currently has a P/E ratio of -2.45, whereas GMAB's P/E ratio is 20.72. In terms of profitability, PRME's ROE is -1.89%, compared to GMAB's ROE of +0.15%. Regarding short-term risk, PRME is more volatile compared to GMAB. This indicates higher risk in terms of short-term price fluctuations for PRME.Check GMAB's competition here
BridgeBio Pharma, Inc. (NASDAQ: BBIO)
PRME vs BBIO Comparison July 2026
Prime Medicine, Inc. (NASDAQ: PRME) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, PRME stands at 543.7M. In comparison, BBIO has a market cap of 16.5B. Regarding current trading prices, PRME is priced at $3.00 on the NASDAQ, while BBIO trades at $84.00.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
PRME currently has a P/E ratio of -2.45, whereas BBIO's P/E ratio is -22.49. In terms of profitability, PRME's ROE is -1.89%, compared to BBIO's ROE of +0.36%. Regarding short-term risk, PRME is more volatile compared to BBIO. This indicates higher risk in terms of short-term price fluctuations for PRME.Check BBIO's competition here
Jazz Pharmaceuticals plc (NASDAQ: JAZZ)
PRME vs JAZZ Comparison July 2026
Prime Medicine, Inc. (NASDAQ: PRME) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, PRME stands at 543.7M. In comparison, JAZZ has a market cap of 16B. Regarding current trading prices, PRME is priced at $3.00 on the NASDAQ, while JAZZ trades at $259.57.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
PRME currently has a P/E ratio of -2.45, whereas JAZZ's P/E ratio is 19.86. In terms of profitability, PRME's ROE is -1.89%, compared to JAZZ's ROE of +0.01%. Regarding short-term risk, PRME is more volatile compared to JAZZ. This indicates higher risk in terms of short-term price fluctuations for PRME.Check JAZZ's competition here
Ascendis Pharma A/S (NASDAQ: ASND)
PRME vs ASND Comparison July 2026
Prime Medicine, Inc. (NASDAQ: PRME) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, PRME stands at 543.7M. In comparison, ASND has a market cap of 15.7B. Regarding current trading prices, PRME is priced at $3.00 on the NASDAQ, while ASND trades at $248.38.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
PRME currently has a P/E ratio of -2.45, whereas ASND's P/E ratio is -104.72. In terms of profitability, PRME's ROE is -1.89%, compared to ASND's ROE of -56.42%. Regarding short-term risk, PRME is more volatile compared to ASND. This indicates higher risk in terms of short-term price fluctuations for PRME.Check ASND's competition here
Exelixis, Inc. (NASDAQ: EXEL)
PRME vs EXEL Comparison July 2026
Prime Medicine, Inc. (NASDAQ: PRME) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, PRME stands at 543.7M. In comparison, EXEL has a market cap of 14B. Regarding current trading prices, PRME is priced at $3.00 on the NASDAQ, while EXEL trades at $55.95.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
PRME currently has a P/E ratio of -2.45, whereas EXEL's P/E ratio is 16.71. In terms of profitability, PRME's ROE is -1.89%, compared to EXEL's ROE of +0.40%. Regarding short-term risk, PRME is more volatile compared to EXEL. This indicates higher risk in terms of short-term price fluctuations for PRME.Check EXEL's competition here
Madrigal Pharmaceuticals, Inc. (NASDAQ: MDGL)
PRME vs MDGL Comparison July 2026
Prime Medicine, Inc. (NASDAQ: PRME) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, PRME stands at 543.7M. In comparison, MDGL has a market cap of 12.7B. Regarding current trading prices, PRME is priced at $3.00 on the NASDAQ, while MDGL trades at $535.88.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
PRME currently has a P/E ratio of -2.45, whereas MDGL's P/E ratio is -43.07. In terms of profitability, PRME's ROE is -1.89%, compared to MDGL's ROE of -0.50%. Regarding short-term risk, PRME is more volatile compared to MDGL. This indicates higher risk in terms of short-term price fluctuations for PRME.Check MDGL's competition here
Karuna Therapeutics, Inc. (NASDAQ: KRTX)
PRME vs KRTX Comparison July 2026
Prime Medicine, Inc. (NASDAQ: PRME) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, PRME stands at 543.7M. In comparison, KRTX has a market cap of 12.6B. Regarding current trading prices, PRME is priced at $3.00 on the NASDAQ, while KRTX trades at $329.83.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
PRME currently has a P/E ratio of -2.45, whereas KRTX's P/E ratio is -28.09. In terms of profitability, PRME's ROE is -1.89%, compared to KRTX's ROE of -0.36%. Regarding short-term risk, PRME is more volatile compared to KRTX. This indicates higher risk in terms of short-term price fluctuations for PRME.Check KRTX's competition here
Axsome Therapeutics, Inc. (NASDAQ: AXSM)
PRME vs AXSM Comparison July 2026
Prime Medicine, Inc. (NASDAQ: PRME) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, PRME stands at 543.7M. In comparison, AXSM has a market cap of 12.3B. Regarding current trading prices, PRME is priced at $3.00 on the NASDAQ, while AXSM trades at $236.35.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
PRME currently has a P/E ratio of -2.45, whereas AXSM's P/E ratio is -62.24. In terms of profitability, PRME's ROE is -1.89%, compared to AXSM's ROE of -2.60%. Regarding short-term risk, PRME is more volatile compared to AXSM. This indicates higher risk in terms of short-term price fluctuations for PRME.Check AXSM's competition here
Arrowhead Pharmaceuticals, Inc. (NASDAQ: ARWR)
PRME vs ARWR Comparison July 2026
Prime Medicine, Inc. (NASDAQ: PRME) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, PRME stands at 543.7M. In comparison, ARWR has a market cap of 12B. Regarding current trading prices, PRME is priced at $3.00 on the NASDAQ, while ARWR trades at $84.21.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
PRME currently has a P/E ratio of -2.45, whereas ARWR's P/E ratio is -39.78. In terms of profitability, PRME's ROE is -1.89%, compared to ARWR's ROE of -0.55%. Regarding short-term risk, PRME is more volatile compared to ARWR. This indicates higher risk in terms of short-term price fluctuations for PRME.Check ARWR's competition here
BioMarin Pharmaceutical Inc. (NASDAQ: BMRN)
PRME vs BMRN Comparison July 2026
Prime Medicine, Inc. (NASDAQ: PRME) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, PRME stands at 543.7M. In comparison, BMRN has a market cap of 11.6B. Regarding current trading prices, PRME is priced at $3.00 on the NASDAQ, while BMRN trades at $62.03.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
PRME currently has a P/E ratio of -2.45, whereas BMRN's P/E ratio is 28.98. In terms of profitability, PRME's ROE is -1.89%, compared to BMRN's ROE of +0.04%. Regarding short-term risk, PRME is more volatile compared to BMRN. This indicates higher risk in terms of short-term price fluctuations for PRME.Check BMRN's competition here
Avidity Biosciences Inc (NASDAQ: RNAM)
PRME vs RNAM Comparison July 2026
Prime Medicine, Inc. (NASDAQ: PRME) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, PRME stands at 543.7M. In comparison, RNAM has a market cap of 11.3B. Regarding current trading prices, PRME is priced at $3.00 on the NASDAQ, while RNAM trades at $72.86.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
PRME currently has a P/E ratio of -2.45, whereas RNAM's P/E ratio is -17.39. In terms of profitability, PRME's ROE is -1.89%, compared to RNAM's ROE of -0.45%. Regarding short-term risk, PRME is more volatile compared to RNAM. This indicates higher risk in terms of short-term price fluctuations for PRME.Check RNAM's competition here
Bio-Techne Corporation (NASDAQ: TECH)
PRME vs TECH Comparison July 2026
Prime Medicine, Inc. (NASDAQ: PRME) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, PRME stands at 543.7M. In comparison, TECH has a market cap of 11.2B. Regarding current trading prices, PRME is priced at $3.00 on the NASDAQ, while TECH trades at $72.04.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
PRME currently has a P/E ratio of -2.45, whereas TECH's P/E ratio is 36.91. In terms of profitability, PRME's ROE is -1.89%, compared to TECH's ROE of +0.05%. Regarding short-term risk, PRME is more volatile compared to TECH. This indicates higher risk in terms of short-term price fluctuations for PRME.Check TECH's competition here
Krystal Biotech, Inc. (NASDAQ: KRYS)
PRME vs KRYS Comparison July 2026
Prime Medicine, Inc. (NASDAQ: PRME) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, PRME stands at 543.7M. In comparison, KRYS has a market cap of 10.4B. Regarding current trading prices, PRME is priced at $3.00 on the NASDAQ, while KRYS trades at $356.13.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
PRME currently has a P/E ratio of -2.45, whereas KRYS's P/E ratio is 47.03. In terms of profitability, PRME's ROE is -1.89%, compared to KRYS's ROE of +0.19%. Regarding short-term risk, PRME is more volatile compared to KRYS. This indicates higher risk in terms of short-term price fluctuations for PRME.Check KRYS's competition here
Summit Therapeutics Inc. (NASDAQ: SMMT)
PRME vs SMMT Comparison July 2026
Prime Medicine, Inc. (NASDAQ: PRME) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, PRME stands at 543.7M. In comparison, SMMT has a market cap of 10.2B. Regarding current trading prices, PRME is priced at $3.00 on the NASDAQ, while SMMT trades at $12.37.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
PRME currently has a P/E ratio of -2.45, whereas SMMT's P/E ratio is -8.19. In terms of profitability, PRME's ROE is -1.89%, compared to SMMT's ROE of -2.04%. Regarding short-term risk, PRME is less volatile compared to SMMT. This indicates lower risk in terms of short-term price fluctuations for PRME.Check SMMT's competition here
Cytokinetics, Incorporated (NASDAQ: CYTK)
PRME vs CYTK Comparison July 2026
Prime Medicine, Inc. (NASDAQ: PRME) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, PRME stands at 543.7M. In comparison, CYTK has a market cap of 10B. Regarding current trading prices, PRME is priced at $3.00 on the NASDAQ, while CYTK trades at $79.68.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
PRME currently has a P/E ratio of -2.45, whereas CYTK's P/E ratio is -13.83. In terms of profitability, PRME's ROE is -1.89%, compared to CYTK's ROE of +1.40%. Regarding short-term risk, PRME is more volatile compared to CYTK. This indicates higher risk in terms of short-term price fluctuations for PRME.Check CYTK's competition here
Halozyme Therapeutics, Inc. (NASDAQ: HALO)
PRME vs HALO Comparison July 2026
Prime Medicine, Inc. (NASDAQ: PRME) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, PRME stands at 543.7M. In comparison, HALO has a market cap of 9.7B. Regarding current trading prices, PRME is priced at $3.00 on the NASDAQ, while HALO trades at $83.75.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
PRME currently has a P/E ratio of -2.45, whereas HALO's P/E ratio is 17.64. In terms of profitability, PRME's ROE is -1.89%, compared to HALO's ROE of +1.26%. Regarding short-term risk, PRME is more volatile compared to HALO. This indicates higher risk in terms of short-term price fluctuations for PRME.Check HALO's competition here
Prometheus Biosciences, Inc. (NASDAQ: RXDX)
PRME vs RXDX Comparison July 2026
Prime Medicine, Inc. (NASDAQ: PRME) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, PRME stands at 543.7M. In comparison, RXDX has a market cap of 9.6B. Regarding current trading prices, PRME is priced at $3.00 on the NASDAQ, while RXDX trades at $199.92.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
PRME currently has a P/E ratio of -2.45, whereas RXDX's P/E ratio is -56.47. In terms of profitability, PRME's ROE is -1.89%, compared to RXDX's ROE of -0.31%. Regarding short-term risk, PRME is more volatile compared to RXDX. This indicates higher risk in terms of short-term price fluctuations for PRME.Check RXDX's competition here
Abivax S.A. (NASDAQ: ABVX)
PRME vs ABVX Comparison July 2026
Prime Medicine, Inc. (NASDAQ: PRME) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, PRME stands at 543.7M. In comparison, ABVX has a market cap of 9.4B. Regarding current trading prices, PRME is priced at $3.00 on the NASDAQ, while ABVX trades at $124.63.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
PRME currently has a P/E ratio of -2.45, whereas ABVX's P/E ratio is -67.09. In terms of profitability, PRME's ROE is -1.89%, compared to ABVX's ROE of -1.65%. Regarding short-term risk, PRME is more volatile compared to ABVX. This indicates higher risk in terms of short-term price fluctuations for PRME.Check ABVX's competition here
Ionis Pharmaceuticals, Inc. (NASDAQ: IONS)
PRME vs IONS Comparison July 2026
Prime Medicine, Inc. (NASDAQ: PRME) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, PRME stands at 543.7M. In comparison, IONS has a market cap of 9.2B. Regarding current trading prices, PRME is priced at $3.00 on the NASDAQ, while IONS trades at $54.79.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
PRME currently has a P/E ratio of -2.45, whereas IONS's P/E ratio is -32.53. In terms of profitability, PRME's ROE is -1.89%, compared to IONS's ROE of -0.59%. Regarding short-term risk, PRME is more volatile compared to IONS. This indicates higher risk in terms of short-term price fluctuations for PRME.Check IONS's competition here
Nuvalent, Inc. (NASDAQ: NUVL)
PRME vs NUVL Comparison July 2026
Prime Medicine, Inc. (NASDAQ: PRME) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, PRME stands at 543.7M. In comparison, NUVL has a market cap of 9.1B. Regarding current trading prices, PRME is priced at $3.00 on the NASDAQ, while NUVL trades at $123.96.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
PRME currently has a P/E ratio of -2.45, whereas NUVL's P/E ratio is -21.79. In terms of profitability, PRME's ROE is -1.89%, compared to NUVL's ROE of -0.43%. Regarding short-term risk, PRME is more volatile compared to NUVL. This indicates higher risk in terms of short-term price fluctuations for PRME.Check NUVL's competition here
Kymera Therapeutics, Inc. (NASDAQ: KYMR)
PRME vs KYMR Comparison July 2026
Prime Medicine, Inc. (NASDAQ: PRME) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, PRME stands at 543.7M. In comparison, KYMR has a market cap of 9.1B. Regarding current trading prices, PRME is priced at $3.00 on the NASDAQ, while KYMR trades at $106.43.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
PRME currently has a P/E ratio of -2.45, whereas KYMR's P/E ratio is -31.18. In terms of profitability, PRME's ROE is -1.89%, compared to KYMR's ROE of -0.25%. Regarding short-term risk, PRME is more volatile compared to KYMR. This indicates higher risk in terms of short-term price fluctuations for PRME.Check KYMR's competition here
Crinetics Pharmaceuticals, Inc. (NASDAQ: CRNX)
PRME vs CRNX Comparison July 2026
Prime Medicine, Inc. (NASDAQ: PRME) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, PRME stands at 543.7M. In comparison, CRNX has a market cap of 8.9B. Regarding current trading prices, PRME is priced at $3.00 on the NASDAQ, while CRNX trades at $83.94.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
PRME currently has a P/E ratio of -2.45, whereas CRNX's P/E ratio is -16.35. In terms of profitability, PRME's ROE is -1.89%, compared to CRNX's ROE of -0.44%. Regarding short-term risk, PRME is more volatile compared to CRNX. This indicates higher risk in terms of short-term price fluctuations for PRME.Check CRNX's competition here
Praxis Precision Medicines, Inc. (NASDAQ: PRAX)
PRME vs PRAX Comparison July 2026
Prime Medicine, Inc. (NASDAQ: PRME) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, PRME stands at 543.7M. In comparison, PRAX has a market cap of 8.8B. Regarding current trading prices, PRME is priced at $3.00 on the NASDAQ, while PRAX trades at $292.74.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
PRME currently has a P/E ratio of -2.45, whereas PRAX's P/E ratio is -23.62. In terms of profitability, PRME's ROE is -1.89%, compared to PRAX's ROE of -0.43%. Regarding short-term risk, PRME is less volatile compared to PRAX. This indicates lower risk in terms of short-term price fluctuations for PRME.Check PRAX's competition here
Alkermes plc (NASDAQ: ALKS)
PRME vs ALKS Comparison July 2026
Prime Medicine, Inc. (NASDAQ: PRME) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, PRME stands at 543.7M. In comparison, ALKS has a market cap of 8.8B. Regarding current trading prices, PRME is priced at $3.00 on the NASDAQ, while ALKS trades at $50.38.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
PRME currently has a P/E ratio of -2.45, whereas ALKS's P/E ratio is 55.51. In terms of profitability, PRME's ROE is -1.89%, compared to ALKS's ROE of +0.09%. Regarding short-term risk, PRME is less volatile compared to ALKS. This indicates lower risk in terms of short-term price fluctuations for PRME.Check ALKS's competition here
ImmunoGen, Inc. (NASDAQ: IMGN)
PRME vs IMGN Comparison July 2026
Prime Medicine, Inc. (NASDAQ: PRME) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, PRME stands at 543.7M. In comparison, IMGN has a market cap of 8.7B. Regarding current trading prices, PRME is priced at $3.00 on the NASDAQ, while IMGN trades at $31.24.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
PRME currently has a P/E ratio of -2.45, whereas IMGN's P/E ratio is -111.55. In terms of profitability, PRME's ROE is -1.89%, compared to IMGN's ROE of -0.93%. Regarding short-term risk, PRME is more volatile compared to IMGN. This indicates higher risk in terms of short-term price fluctuations for PRME.Check IMGN's competition here
Protagonist Therapeutics, Inc. (NASDAQ: PTGX)
PRME vs PTGX Comparison July 2026
Prime Medicine, Inc. (NASDAQ: PRME) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, PRME stands at 543.7M. In comparison, PTGX has a market cap of 8.7B. Regarding current trading prices, PRME is priced at $3.00 on the NASDAQ, while PTGX trades at $135.28.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
PRME currently has a P/E ratio of -2.45, whereas PTGX's P/E ratio is -74.90. In terms of profitability, PRME's ROE is -1.89%, compared to PTGX's ROE of -0.18%. Regarding short-term risk, PRME is more volatile compared to PTGX. This indicates higher risk in terms of short-term price fluctuations for PRME.Check PTGX's competition here
Spyre Therapeutics, Inc. (NASDAQ: SYRE)
PRME vs SYRE Comparison July 2026
Prime Medicine, Inc. (NASDAQ: PRME) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, PRME stands at 543.7M. In comparison, SYRE has a market cap of 8.7B. Regarding current trading prices, PRME is priced at $3.00 on the NASDAQ, while SYRE trades at $97.20.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
PRME currently has a P/E ratio of -2.45, whereas SYRE's P/E ratio is -48.10. In terms of profitability, PRME's ROE is -1.89%, compared to SYRE's ROE of -0.31%. Regarding short-term risk, PRME is less volatile compared to SYRE. This indicates lower risk in terms of short-term price fluctuations for PRME.Check SYRE's competition here
TG Therapeutics, Inc. (NASDAQ: TGTX)
PRME vs TGTX Comparison July 2026
Prime Medicine, Inc. (NASDAQ: PRME) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, PRME stands at 543.7M. In comparison, TGTX has a market cap of 8.5B. Regarding current trading prices, PRME is priced at $3.00 on the NASDAQ, while TGTX trades at $55.50.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
PRME currently has a P/E ratio of -2.45, whereas TGTX's P/E ratio is 19.16. In terms of profitability, PRME's ROE is -1.89%, compared to TGTX's ROE of +0.87%. Regarding short-term risk, PRME is more volatile compared to TGTX. This indicates higher risk in terms of short-term price fluctuations for PRME.Check TGTX's competition here
Blueprint Medicines Corporation (NASDAQ: BPMC)
PRME vs BPMC Comparison July 2026
Prime Medicine, Inc. (NASDAQ: PRME) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, PRME stands at 543.7M. In comparison, BPMC has a market cap of 8.4B. Regarding current trading prices, PRME is priced at $3.00 on the NASDAQ, while BPMC trades at $129.46.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
PRME currently has a P/E ratio of -2.45, whereas BPMC's P/E ratio is -51.58. In terms of profitability, PRME's ROE is -1.89%, compared to BPMC's ROE of -0.31%. Regarding short-term risk, PRME is more volatile compared to BPMC. This indicates higher risk in terms of short-term price fluctuations for PRME.Check BPMC's competition here
Apogee Therapeutics, Inc. (NASDAQ: APGE)
PRME vs APGE Comparison July 2026
Prime Medicine, Inc. (NASDAQ: PRME) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, PRME stands at 543.7M. In comparison, APGE has a market cap of 8.3B. Regarding current trading prices, PRME is priced at $3.00 on the NASDAQ, while APGE trades at $134.11.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
PRME currently has a P/E ratio of -2.45, whereas APGE's P/E ratio is -31.01. In terms of profitability, PRME's ROE is -1.89%, compared to APGE's ROE of -0.33%. Regarding short-term risk, PRME is more volatile compared to APGE. This indicates higher risk in terms of short-term price fluctuations for PRME.Check APGE's competition here
Immunovant, Inc. (NASDAQ: IMVT)
PRME vs IMVT Comparison July 2026
Prime Medicine, Inc. (NASDAQ: PRME) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, PRME stands at 543.7M. In comparison, IMVT has a market cap of 8.2B. Regarding current trading prices, PRME is priced at $3.00 on the NASDAQ, while IMVT trades at $39.01.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
PRME currently has a P/E ratio of -2.45, whereas IMVT's P/E ratio is -15.01. In terms of profitability, PRME's ROE is -1.89%, compared to IMVT's ROE of -0.68%. Regarding short-term risk, PRME is more volatile compared to IMVT. This indicates higher risk in terms of short-term price fluctuations for PRME.Check IMVT's competition here
Cerevel Therapeutics Holdings, Inc. (NASDAQ: CERE)
PRME vs CERE Comparison July 2026
Prime Medicine, Inc. (NASDAQ: PRME) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, PRME stands at 543.7M. In comparison, CERE has a market cap of 8.2B. Regarding current trading prices, PRME is priced at $3.00 on the NASDAQ, while CERE trades at $44.96.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
PRME currently has a P/E ratio of -2.45, whereas CERE's P/E ratio is -16.47. In terms of profitability, PRME's ROE is -1.89%, compared to CERE's ROE of -0.72%. Regarding short-term risk, PRME is more volatile compared to CERE. This indicates higher risk in terms of short-term price fluctuations for PRME.Check CERE's competition here
Vaxcyte, Inc. (NASDAQ: PCVX)
PRME vs PCVX Comparison July 2026
Prime Medicine, Inc. (NASDAQ: PRME) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, PRME stands at 543.7M. In comparison, PCVX has a market cap of 8B. Regarding current trading prices, PRME is priced at $3.00 on the NASDAQ, while PCVX trades at $55.72.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
PRME currently has a P/E ratio of -2.45, whereas PCVX's P/E ratio is -8.07. In terms of profitability, PRME's ROE is -1.89%, compared to PCVX's ROE of -0.33%. Regarding short-term risk, PRME is more volatile compared to PCVX. This indicates higher risk in terms of short-term price fluctuations for PRME.Check PCVX's competition here
Metsera, Inc. (NASDAQ: MTSR)
PRME vs MTSR Comparison July 2026
Prime Medicine, Inc. (NASDAQ: PRME) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, PRME stands at 543.7M. In comparison, MTSR has a market cap of 7.4B. Regarding current trading prices, PRME is priced at $3.00 on the NASDAQ, while MTSR trades at $70.50.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
PRME currently has a P/E ratio of -2.45, whereas MTSR's P/E ratio is -23.58. In terms of profitability, PRME's ROE is -1.89%, compared to MTSR's ROE of -0.61%. Regarding short-term risk, PRME is more volatile compared to MTSR. This indicates higher risk in terms of short-term price fluctuations for PRME.Check MTSR's competition here
ImmunityBio, Inc. (NASDAQ: IBRX)
PRME vs IBRX Comparison July 2026
Prime Medicine, Inc. (NASDAQ: PRME) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, PRME stands at 543.7M. In comparison, IBRX has a market cap of 7.3B. Regarding current trading prices, PRME is priced at $3.00 on the NASDAQ, while IBRX trades at $6.81.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
PRME currently has a P/E ratio of -2.45, whereas IBRX's P/E ratio is -8.22. In terms of profitability, PRME's ROE is -1.89%, compared to IBRX's ROE of +1.39%. Regarding short-term risk, PRME is more volatile compared to IBRX. This indicates higher risk in terms of short-term price fluctuations for PRME.Check IBRX's competition here
Rhythm Pharmaceuticals, Inc. (NASDAQ: RYTM)
PRME vs RYTM Comparison July 2026
Prime Medicine, Inc. (NASDAQ: PRME) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, PRME stands at 543.7M. In comparison, RYTM has a market cap of 7.3B. Regarding current trading prices, PRME is priced at $3.00 on the NASDAQ, while RYTM trades at $109.10.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
PRME currently has a P/E ratio of -2.45, whereas RYTM's P/E ratio is -33.91. In terms of profitability, PRME's ROE is -1.89%, compared to RYTM's ROE of -2.03%. Regarding short-term risk, PRME is more volatile compared to RYTM. This indicates higher risk in terms of short-term price fluctuations for PRME.Check RYTM's competition here
Mirum Pharmaceuticals, Inc. (NASDAQ: MIRM)
PRME vs MIRM Comparison July 2026
Prime Medicine, Inc. (NASDAQ: PRME) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, PRME stands at 543.7M. In comparison, MIRM has a market cap of 7B. Regarding current trading prices, PRME is priced at $3.00 on the NASDAQ, while MIRM trades at $112.42.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
PRME currently has a P/E ratio of -2.45, whereas MIRM's P/E ratio is -8.39. In terms of profitability, PRME's ROE is -1.89%, compared to MIRM's ROE of -2.89%. Regarding short-term risk, PRME is more volatile compared to MIRM. This indicates higher risk in terms of short-term price fluctuations for PRME.Check MIRM's competition here
Cogent Biosciences, Inc. (NASDAQ: COGT)
PRME vs COGT Comparison July 2026
Prime Medicine, Inc. (NASDAQ: PRME) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, PRME stands at 543.7M. In comparison, COGT has a market cap of 6.9B. Regarding current trading prices, PRME is priced at $3.00 on the NASDAQ, while COGT trades at $39.57.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
PRME currently has a P/E ratio of -2.45, whereas COGT's P/E ratio is -19.17. In terms of profitability, PRME's ROE is -1.89%, compared to COGT's ROE of -0.83%. Regarding short-term risk, PRME is more volatile compared to COGT. This indicates higher risk in terms of short-term price fluctuations for PRME.Check COGT's competition here
Merus N.V. (NASDAQ: MRUS)
PRME vs MRUS Comparison July 2026
Prime Medicine, Inc. (NASDAQ: PRME) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, PRME stands at 543.7M. In comparison, MRUS has a market cap of 6.8B. Regarding current trading prices, PRME is priced at $3.00 on the NASDAQ, while MRUS trades at $90.00.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
PRME currently has a P/E ratio of -2.45, whereas MRUS's P/E ratio is -17.05. In terms of profitability, PRME's ROE is -1.89%, compared to MRUS's ROE of -0.46%. Regarding short-term risk, PRME is more volatile compared to MRUS. This indicates higher risk in terms of short-term price fluctuations for PRME.Check MRUS's competition here
Arcellx, Inc. (NASDAQ: ACLX)
PRME vs ACLX Comparison July 2026
Prime Medicine, Inc. (NASDAQ: PRME) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, PRME stands at 543.7M. In comparison, ACLX has a market cap of 6.7B. Regarding current trading prices, PRME is priced at $3.00 on the NASDAQ, while ACLX trades at $115.07.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
PRME currently has a P/E ratio of -2.45, whereas ACLX's P/E ratio is -28.27. In terms of profitability, PRME's ROE is -1.89%, compared to ACLX's ROE of -0.55%. Regarding short-term risk, PRME is more volatile compared to ACLX. This indicates higher risk in terms of short-term price fluctuations for PRME.Check ACLX's competition here
Reata Pharmaceuticals, Inc. (NASDAQ: RETA)
PRME vs RETA Comparison July 2026
Prime Medicine, Inc. (NASDAQ: PRME) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, PRME stands at 543.7M. In comparison, RETA has a market cap of 6.6B. Regarding current trading prices, PRME is priced at $3.00 on the NASDAQ, while RETA trades at $172.36.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
PRME currently has a P/E ratio of -2.45, whereas RETA's P/E ratio is -66.29. In terms of profitability, PRME's ROE is -1.89%, compared to RETA's ROE of +0.47%. Regarding short-term risk, PRME is more volatile compared to RETA. This indicates higher risk in terms of short-term price fluctuations for PRME.Check RETA's competition here
Erasca, Inc. (NASDAQ: ERAS)
PRME vs ERAS Comparison July 2026
Prime Medicine, Inc. (NASDAQ: PRME) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, PRME stands at 543.7M. In comparison, ERAS has a market cap of 6.6B. Regarding current trading prices, PRME is priced at $3.00 on the NASDAQ, while ERAS trades at $18.00.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
PRME currently has a P/E ratio of -2.45, whereas ERAS's P/E ratio is -20.29. In terms of profitability, PRME's ROE is -1.89%, compared to ERAS's ROE of -0.77%. Regarding short-term risk, PRME is more volatile compared to ERAS. This indicates higher risk in terms of short-term price fluctuations for PRME.Check ERAS's competition here
CG Oncology Inc. (NASDAQ: CGON)
PRME vs CGON Comparison July 2026
Prime Medicine, Inc. (NASDAQ: PRME) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, PRME stands at 543.7M. In comparison, CGON has a market cap of 6.5B. Regarding current trading prices, PRME is priced at $3.00 on the NASDAQ, while CGON trades at $71.85.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
PRME currently has a P/E ratio of -2.45, whereas CGON's P/E ratio is -31.55. In terms of profitability, PRME's ROE is -1.89%, compared to CGON's ROE of -0.23%. Regarding short-term risk, PRME is more volatile compared to CGON. This indicates higher risk in terms of short-term price fluctuations for PRME.Check CGON's competition here
Xenon Pharmaceuticals Inc. (NASDAQ: XENE)
PRME vs XENE Comparison July 2026
Prime Medicine, Inc. (NASDAQ: PRME) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, PRME stands at 543.7M. In comparison, XENE has a market cap of 6.4B. Regarding current trading prices, PRME is priced at $3.00 on the NASDAQ, while XENE trades at $65.23.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
PRME currently has a P/E ratio of -2.45, whereas XENE's P/E ratio is -14.00. In terms of profitability, PRME's ROE is -1.89%, compared to XENE's ROE of -0.49%. Regarding short-term risk, PRME is more volatile compared to XENE. This indicates higher risk in terms of short-term price fluctuations for PRME.Check XENE's competition here
Belite Bio, Inc (NASDAQ: BLTE)
PRME vs BLTE Comparison July 2026
Prime Medicine, Inc. (NASDAQ: PRME) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, PRME stands at 543.7M. In comparison, BLTE has a market cap of 6.4B. Regarding current trading prices, PRME is priced at $3.00 on the NASDAQ, while BLTE trades at $155.23.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
PRME currently has a P/E ratio of -2.45, whereas BLTE's P/E ratio is -84.72. In terms of profitability, PRME's ROE is -1.89%, compared to BLTE's ROE of -0.18%. Regarding short-term risk, PRME is more volatile compared to BLTE. This indicates higher risk in terms of short-term price fluctuations for PRME.Check BLTE's competition here
PTC Therapeutics, Inc. (NASDAQ: PTCT)
PRME vs PTCT Comparison July 2026
Prime Medicine, Inc. (NASDAQ: PRME) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, PRME stands at 543.7M. In comparison, PTCT has a market cap of 6.3B. Regarding current trading prices, PRME is priced at $3.00 on the NASDAQ, while PTCT trades at $73.72.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
PRME currently has a P/E ratio of -2.45, whereas PTCT's P/E ratio is -32.53. In terms of profitability, PRME's ROE is -1.89%, compared to PTCT's ROE of +1.00%. Regarding short-term risk, PRME is more volatile compared to PTCT. This indicates higher risk in terms of short-term price fluctuations for PRME.Check PTCT's competition here
Centessa Pharmaceuticals plc (NASDAQ: CNTA)
PRME vs CNTA Comparison July 2026
Prime Medicine, Inc. (NASDAQ: PRME) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, PRME stands at 543.7M. In comparison, CNTA has a market cap of 6.3B. Regarding current trading prices, PRME is priced at $3.00 on the NASDAQ, while CNTA trades at $40.50.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
PRME currently has a P/E ratio of -2.45, whereas CNTA's P/E ratio is -22.63. In terms of profitability, PRME's ROE is -1.89%, compared to CNTA's ROE of -0.60%. Regarding short-term risk, PRME is more volatile compared to CNTA. This indicates higher risk in terms of short-term price fluctuations for PRME.Check CNTA's competition here
Ligand Pharmaceuticals Incorporated (NASDAQ: LGND)
PRME vs LGND Comparison July 2026
Prime Medicine, Inc. (NASDAQ: PRME) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, PRME stands at 543.7M. In comparison, LGND has a market cap of 6B. Regarding current trading prices, PRME is priced at $3.00 on the NASDAQ, while LGND trades at $297.85.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
PRME currently has a P/E ratio of -2.45, whereas LGND's P/E ratio is 35.67. In terms of profitability, PRME's ROE is -1.89%, compared to LGND's ROE of +0.16%. Regarding short-term risk, PRME is more volatile compared to LGND. This indicates higher risk in terms of short-term price fluctuations for PRME.Check LGND's competition here
Scholar Rock Holding Corporation (NASDAQ: SRRK)
PRME vs SRRK Comparison July 2026
Prime Medicine, Inc. (NASDAQ: PRME) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, PRME stands at 543.7M. In comparison, SRRK has a market cap of 5.9B. Regarding current trading prices, PRME is priced at $3.00 on the NASDAQ, while SRRK trades at $48.51.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
PRME currently has a P/E ratio of -2.45, whereas SRRK's P/E ratio is -13.63. In terms of profitability, PRME's ROE is -1.89%, compared to SRRK's ROE of -1.64%. Regarding short-term risk, PRME is more volatile compared to SRRK. This indicates higher risk in terms of short-term price fluctuations for PRME.Check SRRK's competition here
Cidara Therapeutics, Inc. (NASDAQ: CDTX)
PRME vs CDTX Comparison July 2026
Prime Medicine, Inc. (NASDAQ: PRME) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, PRME stands at 543.7M. In comparison, CDTX has a market cap of 5.6B. Regarding current trading prices, PRME is priced at $3.00 on the NASDAQ, while CDTX trades at $221.38.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
PRME currently has a P/E ratio of -2.45, whereas CDTX's P/E ratio is -19.77. In terms of profitability, PRME's ROE is -1.89%, compared to CDTX's ROE of -0.37%. Regarding short-term risk, PRME is more volatile compared to CDTX. This indicates higher risk in terms of short-term price fluctuations for PRME.Check CDTX's competition here
Abcam plc (NASDAQ: ABCM)
PRME vs ABCM Comparison July 2026
Prime Medicine, Inc. (NASDAQ: PRME) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, PRME stands at 543.7M. In comparison, ABCM has a market cap of 5.5B. Regarding current trading prices, PRME is priced at $3.00 on the NASDAQ, while ABCM trades at $23.99.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
PRME currently has a P/E ratio of -2.45, whereas ABCM's P/E ratio is 2399.00. In terms of profitability, PRME's ROE is -1.89%, compared to ABCM's ROE of -0.01%. Regarding short-term risk, PRME is more volatile compared to ABCM. This indicates higher risk in terms of short-term price fluctuations for PRME.Check ABCM's competition here
IVERIC bio, Inc. (NASDAQ: ISEE)
PRME vs ISEE Comparison July 2026
Prime Medicine, Inc. (NASDAQ: PRME) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, PRME stands at 543.7M. In comparison, ISEE has a market cap of 5.5B. Regarding current trading prices, PRME is priced at $3.00 on the NASDAQ, while ISEE trades at $39.95.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
PRME currently has a P/E ratio of -2.45, whereas ISEE's P/E ratio is -22.44. In terms of profitability, PRME's ROE is -1.89%, compared to ISEE's ROE of -0.39%. Regarding short-term risk, PRME is more volatile compared to ISEE. This indicates higher risk in terms of short-term price fluctuations for PRME.Check ISEE's competition here
Travere Therapeutics, Inc. (NASDAQ: TVTX)
PRME vs TVTX Comparison July 2026
Prime Medicine, Inc. (NASDAQ: PRME) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, PRME stands at 543.7M. In comparison, TVTX has a market cap of 5.3B. Regarding current trading prices, PRME is priced at $3.00 on the NASDAQ, while TVTX trades at $55.63.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
PRME currently has a P/E ratio of -2.45, whereas TVTX's P/E ratio is -257.64. In terms of profitability, PRME's ROE is -1.89%, compared to TVTX's ROE of -0.27%. Regarding short-term risk, PRME is more volatile compared to TVTX. This indicates higher risk in terms of short-term price fluctuations for PRME.Check TVTX's competition here
Apellis Pharmaceuticals, Inc. (NASDAQ: APLS)
PRME vs APLS Comparison July 2026
Prime Medicine, Inc. (NASDAQ: PRME) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, PRME stands at 543.7M. In comparison, APLS has a market cap of 5.3B. Regarding current trading prices, PRME is priced at $3.00 on the NASDAQ, while APLS trades at $41.03.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
PRME currently has a P/E ratio of -2.45, whereas APLS's P/E ratio is 38.35. In terms of profitability, PRME's ROE is -1.89%, compared to APLS's ROE of +0.40%. Regarding short-term risk, PRME is more volatile compared to APLS. This indicates higher risk in terms of short-term price fluctuations for PRME.Check APLS's competition here
Terns Pharmaceuticals, Inc. (NASDAQ: TERN)
PRME vs TERN Comparison July 2026
Prime Medicine, Inc. (NASDAQ: PRME) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, PRME stands at 543.7M. In comparison, TERN has a market cap of 4.8B. Regarding current trading prices, PRME is priced at $3.00 on the NASDAQ, while TERN trades at $52.95.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
PRME currently has a P/E ratio of -2.45, whereas TERN's P/E ratio is -51.41. In terms of profitability, PRME's ROE is -1.89%, compared to TERN's ROE of -0.20%. Regarding short-term risk, PRME is more volatile compared to TERN. This indicates higher risk in terms of short-term price fluctuations for PRME.Check TERN's competition here
Definium Therapeutics, Inc. (NASDAQ: DFTX)
PRME vs DFTX Comparison July 2026
Prime Medicine, Inc. (NASDAQ: PRME) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, PRME stands at 543.7M. In comparison, DFTX has a market cap of 4.7B. Regarding current trading prices, PRME is priced at $3.00 on the NASDAQ, while DFTX trades at $41.55.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
PRME currently has a P/E ratio of -2.45, whereas DFTX's P/E ratio is N/A. In terms of profitability, PRME's ROE is -1.89%, compared to DFTX's ROE of -1.02%. Regarding short-term risk, PRME is more volatile compared to DFTX. This indicates higher risk in terms of short-term price fluctuations for PRME.Check DFTX's competition here
Veradermics, Incorporated (NYSE: MANE)
PRME vs MANE Comparison July 2026
Prime Medicine, Inc. (NASDAQ: PRME) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, PRME stands at 543.7M. In comparison, MANE has a market cap of 4.7B. Regarding current trading prices, PRME is priced at $3.00 on the NASDAQ, while MANE trades at $113.04.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
PRME currently has a P/E ratio of -2.45, whereas MANE's P/E ratio is -35.45. In terms of profitability, PRME's ROE is -1.89%, compared to MANE's ROE of -0.84%. Regarding short-term risk, PRME is more volatile compared to MANE. This indicates higher risk in terms of short-term price fluctuations for PRME.Check MANE's competition here
Amicus Therapeutics, Inc. (NASDAQ: FOLD)
PRME vs FOLD Comparison July 2026
Prime Medicine, Inc. (NASDAQ: PRME) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, PRME stands at 543.7M. In comparison, FOLD has a market cap of 4.5B. Regarding current trading prices, PRME is priced at $3.00 on the NASDAQ, while FOLD trades at $14.49.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
PRME currently has a P/E ratio of -2.45, whereas FOLD's P/E ratio is -161.00. In terms of profitability, PRME's ROE is -1.89%, compared to FOLD's ROE of -0.12%. Regarding short-term risk, PRME is more volatile compared to FOLD. This indicates higher risk in terms of short-term price fluctuations for PRME.Check FOLD's competition here
CRISPR Therapeutics AG (NASDAQ: CRSP)
PRME vs CRSP Comparison July 2026
Prime Medicine, Inc. (NASDAQ: PRME) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, PRME stands at 543.7M. In comparison, CRSP has a market cap of 4.5B. Regarding current trading prices, PRME is priced at $3.00 on the NASDAQ, while CRSP trades at $47.35.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
PRME currently has a P/E ratio of -2.45, whereas CRSP's P/E ratio is -9.15. In terms of profitability, PRME's ROE is -1.89%, compared to CRSP's ROE of -0.31%. Regarding short-term risk, PRME is more volatile compared to CRSP. This indicates higher risk in terms of short-term price fluctuations for PRME.Check CRSP's competition here
Akero Therapeutics, Inc. (NASDAQ: AKRO)
PRME vs AKRO Comparison July 2026
Prime Medicine, Inc. (NASDAQ: PRME) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, PRME stands at 543.7M. In comparison, AKRO has a market cap of 4.5B. Regarding current trading prices, PRME is priced at $3.00 on the NASDAQ, while AKRO trades at $54.65.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
PRME currently has a P/E ratio of -2.45, whereas AKRO's P/E ratio is -14.57. In terms of profitability, PRME's ROE is -1.89%, compared to AKRO's ROE of -0.22%. Regarding short-term risk, PRME is more volatile compared to AKRO. This indicates higher risk in terms of short-term price fluctuations for PRME.Check AKRO's competition here
Edgewise Therapeutics, Inc. (NASDAQ: EWTX)
PRME vs EWTX Comparison July 2026
Prime Medicine, Inc. (NASDAQ: PRME) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, PRME stands at 543.7M. In comparison, EWTX has a market cap of 4.5B. Regarding current trading prices, PRME is priced at $3.00 on the NASDAQ, while EWTX trades at $40.78.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
PRME currently has a P/E ratio of -2.45, whereas EWTX's P/E ratio is -25.06. In terms of profitability, PRME's ROE is -1.89%, compared to EWTX's ROE of -0.33%. Regarding short-term risk, PRME is more volatile compared to EWTX. This indicates higher risk in terms of short-term price fluctuations for PRME.Check EWTX's competition here
Alpine Immune Sciences, Inc. (NASDAQ: ALPN)
PRME vs ALPN Comparison July 2026
Prime Medicine, Inc. (NASDAQ: PRME) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, PRME stands at 543.7M. In comparison, ALPN has a market cap of 4.5B. Regarding current trading prices, PRME is priced at $3.00 on the NASDAQ, while ALPN trades at $64.97.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
PRME currently has a P/E ratio of -2.45, whereas ALPN's P/E ratio is -101.52. In terms of profitability, PRME's ROE is -1.89%, compared to ALPN's ROE of -0.13%. Regarding short-term risk, PRME is more volatile compared to ALPN. This indicates higher risk in terms of short-term price fluctuations for PRME.Check ALPN's competition here
Caris Life Sciences, Inc. (NASDAQ: CAI)
PRME vs CAI Comparison July 2026
Prime Medicine, Inc. (NASDAQ: PRME) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, PRME stands at 543.7M. In comparison, CAI has a market cap of 4.4B. Regarding current trading prices, PRME is priced at $3.00 on the NASDAQ, while CAI trades at $15.76.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
PRME currently has a P/E ratio of -2.45, whereas CAI's P/E ratio is -85.97. In terms of profitability, PRME's ROE is -1.89%, compared to CAI's ROE of +0.06%. Regarding short-term risk, PRME is more volatile compared to CAI. This indicates higher risk in terms of short-term price fluctuations for PRME.Check CAI's competition here
Dianthus Therapeutics, Inc. (NASDAQ: DNTH)
PRME vs DNTH Comparison July 2026
Prime Medicine, Inc. (NASDAQ: PRME) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, PRME stands at 543.7M. In comparison, DNTH has a market cap of 4.4B. Regarding current trading prices, PRME is priced at $3.00 on the NASDAQ, while DNTH trades at $102.47.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
PRME currently has a P/E ratio of -2.45, whereas DNTH's P/E ratio is -25.30. In terms of profitability, PRME's ROE is -1.89%, compared to DNTH's ROE of -0.02%. Regarding short-term risk, PRME is more volatile compared to DNTH. This indicates higher risk in terms of short-term price fluctuations for PRME.Check DNTH's competition here
ACADIA Pharmaceuticals Inc. (NASDAQ: ACAD)
PRME vs ACAD Comparison July 2026
Prime Medicine, Inc. (NASDAQ: PRME) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, PRME stands at 543.7M. In comparison, ACAD has a market cap of 4.3B. Regarding current trading prices, PRME is priced at $3.00 on the NASDAQ, while ACAD trades at $25.71.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
PRME currently has a P/E ratio of -2.45, whereas ACAD's P/E ratio is 12.45. In terms of profitability, PRME's ROE is -1.89%, compared to ACAD's ROE of +0.36%. Regarding short-term risk, PRME is more volatile compared to ACAD. This indicates higher risk in terms of short-term price fluctuations for PRME.Check ACAD's competition here
Dyne Therapeutics, Inc. (NASDAQ: DYN)
PRME vs DYN Comparison July 2026
Prime Medicine, Inc. (NASDAQ: PRME) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, PRME stands at 543.7M. In comparison, DYN has a market cap of 4.2B. Regarding current trading prices, PRME is priced at $3.00 on the NASDAQ, while DYN trades at $25.68.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
PRME currently has a P/E ratio of -2.45, whereas DYN's P/E ratio is -7.96. In terms of profitability, PRME's ROE is -1.89%, compared to DYN's ROE of -0.58%. Regarding short-term risk, PRME is more volatile compared to DYN. This indicates higher risk in terms of short-term price fluctuations for PRME.Check DYN's competition here
Opthea Limited (NASDAQ: OPT)
PRME vs OPT Comparison July 2026
Prime Medicine, Inc. (NASDAQ: PRME) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, PRME stands at 543.7M. In comparison, OPT has a market cap of 4.2B. Regarding current trading prices, PRME is priced at $3.00 on the NASDAQ, while OPT trades at $3.41.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
PRME currently has a P/E ratio of -2.45, whereas OPT's P/E ratio is -1.52. In terms of profitability, PRME's ROE is -1.89%, compared to OPT's ROE of +1.18%. Regarding short-term risk, PRME is more volatile compared to OPT. This indicates higher risk in terms of short-term price fluctuations for PRME.Check OPT's competition here
Mirati Therapeutics, Inc. (NASDAQ: MRTX)
PRME vs MRTX Comparison July 2026
Prime Medicine, Inc. (NASDAQ: PRME) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, PRME stands at 543.7M. In comparison, MRTX has a market cap of 4.1B. Regarding current trading prices, PRME is priced at $3.00 on the NASDAQ, while MRTX trades at $58.70.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
PRME currently has a P/E ratio of -2.45, whereas MRTX's P/E ratio is -4.82. In terms of profitability, PRME's ROE is -1.89%, compared to MRTX's ROE of -0.62%. Regarding short-term risk, PRME is more volatile compared to MRTX. This indicates higher risk in terms of short-term price fluctuations for PRME.Check MRTX's competition here
Viking Therapeutics, Inc. (NASDAQ: VKTX)
PRME vs VKTX Comparison July 2026
Prime Medicine, Inc. (NASDAQ: PRME) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, PRME stands at 543.7M. In comparison, VKTX has a market cap of 4B. Regarding current trading prices, PRME is priced at $3.00 on the NASDAQ, while VKTX trades at $33.21.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
PRME currently has a P/E ratio of -2.45, whereas VKTX's P/E ratio is -8.42. In terms of profitability, PRME's ROE is -1.89%, compared to VKTX's ROE of -0.71%. Regarding short-term risk, PRME is more volatile compared to VKTX. This indicates higher risk in terms of short-term price fluctuations for PRME.Check VKTX's competition here
Celcuity Inc. (NASDAQ: CELC)
PRME vs CELC Comparison July 2026
Prime Medicine, Inc. (NASDAQ: PRME) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, PRME stands at 543.7M. In comparison, CELC has a market cap of 4B. Regarding current trading prices, PRME is priced at $3.00 on the NASDAQ, while CELC trades at $82.00.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
PRME currently has a P/E ratio of -2.45, whereas CELC's P/E ratio is -21.09. In terms of profitability, PRME's ROE is -1.89%, compared to CELC's ROE of -2.45%. Regarding short-term risk, PRME is more volatile compared to CELC. This indicates higher risk in terms of short-term price fluctuations for PRME.Check CELC's competition here
Catalyst Pharmaceuticals, Inc. (NASDAQ: CPRX)
PRME vs CPRX Comparison July 2026
Prime Medicine, Inc. (NASDAQ: PRME) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, PRME stands at 543.7M. In comparison, CPRX has a market cap of 3.9B. Regarding current trading prices, PRME is priced at $3.00 on the NASDAQ, while CPRX trades at $31.49.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
PRME currently has a P/E ratio of -2.45, whereas CPRX's P/E ratio is 12.30. In terms of profitability, PRME's ROE is -1.89%, compared to CPRX's ROE of +0.24%. Regarding short-term risk, PRME is more volatile compared to CPRX. This indicates higher risk in terms of short-term price fluctuations for PRME.Check CPRX's competition here
Enliven Therapeutics, Inc. (NASDAQ: ELVN)
PRME vs ELVN Comparison July 2026
Prime Medicine, Inc. (NASDAQ: PRME) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, PRME stands at 543.7M. In comparison, ELVN has a market cap of 3.8B. Regarding current trading prices, PRME is priced at $3.00 on the NASDAQ, while ELVN trades at $53.06.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
PRME currently has a P/E ratio of -2.45, whereas ELVN's P/E ratio is -31.58. In terms of profitability, PRME's ROE is -1.89%, compared to ELVN's ROE of -0.21%. Regarding short-term risk, PRME is more volatile compared to ELVN. This indicates higher risk in terms of short-term price fluctuations for PRME.Check ELVN's competition here
RayzeBio, Inc. Common Stock (NASDAQ: RYZB)
PRME vs RYZB Comparison July 2026
Prime Medicine, Inc. (NASDAQ: PRME) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, PRME stands at 543.7M. In comparison, RYZB has a market cap of 3.8B. Regarding current trading prices, PRME is priced at $3.00 on the NASDAQ, while RYZB trades at $62.49.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
PRME currently has a P/E ratio of -2.45, whereas RYZB's P/E ratio is -57.86. In terms of profitability, PRME's ROE is -1.89%, compared to RYZB's ROE of +0.83%. Regarding short-term risk, PRME is more volatile compared to RYZB. This indicates higher risk in terms of short-term price fluctuations for PRME.Check RYZB's competition here
Denali Therapeutics Inc. (NASDAQ: DNLI)
PRME vs DNLI Comparison July 2026
Prime Medicine, Inc. (NASDAQ: PRME) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, PRME stands at 543.7M. In comparison, DNLI has a market cap of 3.7B. Regarding current trading prices, PRME is priced at $3.00 on the NASDAQ, while DNLI trades at $23.42.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
PRME currently has a P/E ratio of -2.45, whereas DNLI's P/E ratio is -8.18. In terms of profitability, PRME's ROE is -1.89%, compared to DNLI's ROE of -0.52%. Regarding short-term risk, PRME is more volatile compared to DNLI. This indicates higher risk in terms of short-term price fluctuations for PRME.Check DNLI's competition here
CymaBay Therapeutics, Inc. (NASDAQ: CBAY)
PRME vs CBAY Comparison July 2026
Prime Medicine, Inc. (NASDAQ: PRME) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, PRME stands at 543.7M. In comparison, CBAY has a market cap of 3.7B. Regarding current trading prices, PRME is priced at $3.00 on the NASDAQ, while CBAY trades at $32.48.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
PRME currently has a P/E ratio of -2.45, whereas CBAY's P/E ratio is -32.81. In terms of profitability, PRME's ROE is -1.89%, compared to CBAY's ROE of -0.64%. Regarding short-term risk, PRME is more volatile compared to CBAY. This indicates higher risk in terms of short-term price fluctuations for PRME.Check CBAY's competition here
NewAmsterdam Pharma Company N.V. (NASDAQ: NAMSW)
PRME vs NAMSW Comparison July 2026
Prime Medicine, Inc. (NASDAQ: PRME) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, PRME stands at 543.7M. In comparison, NAMSW has a market cap of 3.6B. Regarding current trading prices, PRME is priced at $3.00 on the NASDAQ, while NAMSW trades at $18.35.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
PRME currently has a P/E ratio of -2.45, whereas NAMSW's P/E ratio is -10.75. In terms of profitability, PRME's ROE is -1.89%, compared to NAMSW's ROE of -0.30%. Regarding short-term risk, PRME is more volatile compared to NAMSW. This indicates higher risk in terms of short-term price fluctuations for PRME.Check NAMSW's competition here
Adaptive Biotechnologies Corporation (NASDAQ: ADPT)
PRME vs ADPT Comparison July 2026
Prime Medicine, Inc. (NASDAQ: PRME) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, PRME stands at 543.7M. In comparison, ADPT has a market cap of 3.6B. Regarding current trading prices, PRME is priced at $3.00 on the NASDAQ, while ADPT trades at $22.47.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
PRME currently has a P/E ratio of -2.45, whereas ADPT's P/E ratio is -41.74. In terms of profitability, PRME's ROE is -1.89%, compared to ADPT's ROE of -0.24%. Regarding short-term risk, PRME is more volatile compared to ADPT. This indicates higher risk in terms of short-term price fluctuations for PRME.Check ADPT's competition here
Legend Biotech Corporation (NASDAQ: LEGN)
PRME vs LEGN Comparison July 2026
Prime Medicine, Inc. (NASDAQ: PRME) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, PRME stands at 543.7M. In comparison, LEGN has a market cap of 3.6B. Regarding current trading prices, PRME is priced at $3.00 on the NASDAQ, while LEGN trades at $18.88.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
PRME currently has a P/E ratio of -2.45, whereas LEGN's P/E ratio is -28.34. In terms of profitability, PRME's ROE is -1.89%, compared to LEGN's ROE of -0.25%. Regarding short-term risk, PRME is more volatile compared to LEGN. This indicates higher risk in terms of short-term price fluctuations for PRME.Check LEGN's competition here
SpringWorks Therapeutics, Inc. (NASDAQ: SWTX)
PRME vs SWTX Comparison July 2026
Prime Medicine, Inc. (NASDAQ: PRME) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, PRME stands at 543.7M. In comparison, SWTX has a market cap of 3.5B. Regarding current trading prices, PRME is priced at $3.00 on the NASDAQ, while SWTX trades at $46.99.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
PRME currently has a P/E ratio of -2.45, whereas SWTX's P/E ratio is -13.78. In terms of profitability, PRME's ROE is -1.89%, compared to SWTX's ROE of -0.47%. Regarding short-term risk, PRME is more volatile compared to SWTX. This indicates higher risk in terms of short-term price fluctuations for PRME.Check SWTX's competition here
NewAmsterdam Pharma Company N.V. (NASDAQ: NAMS)
PRME vs NAMS Comparison July 2026
Prime Medicine, Inc. (NASDAQ: PRME) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, PRME stands at 543.7M. In comparison, NAMS has a market cap of 3.5B. Regarding current trading prices, PRME is priced at $3.00 on the NASDAQ, while NAMS trades at $28.08.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
PRME currently has a P/E ratio of -2.45, whereas NAMS's P/E ratio is -19.01. In terms of profitability, PRME's ROE is -1.89%, compared to NAMS's ROE of -0.30%. Regarding short-term risk, PRME is less volatile compared to NAMS. This indicates lower risk in terms of short-term price fluctuations for PRME.Check NAMS's competition here
Arcus Biosciences, Inc. (NYSE: RCUS)
PRME vs RCUS Comparison July 2026
Prime Medicine, Inc. (NASDAQ: PRME) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, PRME stands at 543.7M. In comparison, RCUS has a market cap of 3.5B. Regarding current trading prices, PRME is priced at $3.00 on the NASDAQ, while RCUS trades at $26.83.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
PRME currently has a P/E ratio of -2.45, whereas RCUS's P/E ratio is -8.56. In terms of profitability, PRME's ROE is -1.89%, compared to RCUS's ROE of -0.69%. Regarding short-term risk, PRME is more volatile compared to RCUS. This indicates higher risk in terms of short-term price fluctuations for PRME.Check RCUS's competition here